Novartis, BMS partner to evaluate new lung cancer therapies
The combination therapies will be evaluated in two Phase I/II trials by Novartis in patients with non-small cell lung cancer (NSCLC). Novartis’ three molecularly targeted oncology therapies include
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.